Purchase Order 75N93025P01034

Award Date 7/12/25
Potential Completion Date 7/11/26
Potential Value $25K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a firm-fixed-price purchase order to Illumina, Inc. for a NEXTSEQ 2000 SILVER SUPPORT PLAN. The potential value of the contract is $48,209.00, with a completion date of April 2, 2025. This contract is not set aside and is for the provision of sequencing and array-based solutions to support genomic analysis and life science research. Illumina, a for-profit...
This is a $14,997.46 firm fixed price delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Illumina, Inc., a for-profit manufacturer of genetic analysis instruments and reagents. The contract is not set aside for any specific business size or type. Under this award, Illumina will provide a range of its NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, as well as accompanying reagents, consumables, sample preparation kits,...
This firm fixed-price delivery order contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The $12,058.24 contract is for the procurement of Illumina sequencing kits and does not have a set-aside designation. Illumina has been awarded multiple prime federal contracts and grants, primarily focused on providing advanced genomic sequencing...
This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Illumina, Inc., a manufacturer of sequencing and genomic analysis solutions. The $5,212.06 contract is for the provision of next-generation sequencing kits to support genomic research and diagnostics. Illumina has a history of providing sequencing systems, reagents, and associated services to federal agencies...
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Illumina, Inc., a for-profit manufacturer of genomic sequencing instruments and reagents. The contract, valued at $12,875.00, is for sequencing services to support NIAID's research and diagnostic efforts. Illumina has previously been awarded other prime federal contracts and subcontracts by...
This is a $48,209 firm fixed price purchase order awarded by the National Institute on Deafness and Other Communication Disorders (NIDCD), a civilian agency within the National Institutes of Health (NIH), to Illumina, Inc. The contract provides a NEXT SEQ 2000 SILVER SUPPORT PLAN with a completion date of September 12, 2025. Illumina, a for-profit manufacturer of genomic sequencing and analysis equipment and reagents, has previously received other prime federal contracts and subcontracts from...
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Illumina, Inc., a manufacturer of genomic sequencing instruments and reagents. The contract, valued at $4,037.50, is for the delivery of Illumina's NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, along with accompanying reagents, consumables, and support services. The contract has no set-aside designation....
This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Illumina, Inc. The $93,525.44 contract provides a 12-month silver support plan for two NextSeq 2000 sequencing systems. No set-aside was used. Illumina is a manufacturer and provider of genomic analysis instruments and reagents, and has previously received prime federal contracts and sub-awards from the NIH, CDC,...
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. government, to Illumina, Inc. for a service agreement for a NextSeq 2000 sequencing system. The total ceiling value of the contract is $48,209.00 and it has an ultimate completion date of December 15, 2025. This contract does not have a set-aside designation. Illumina is a manufacturer of genomic sequencing instruments and reagents, and...
This is a $6,935.22 firm fixed-price purchase order contract awarded to Illumina, Inc., a manufacturer of sequencing and array-based genomic analysis solutions, by the National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health (NIH). The contract, which has no set-aside designation, is for the provision of sequencing systems, reagents, and services to support genomic research and diagnostics across various federal agencies. Illumina has...

This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The $24,999 contract is for a NEXTSEQ 2000 BRONZE SUPPORT PLAN (AMBIS 2259765) with a performance period through July 11, 2026. The contract does not utilize any set-aside designation. Illumina has been awarded numerous federal contracts and grants by agencies such as the NIH, CDC, USDA, VA, and FDA, primarily for the procurement of advanced sequencing instruments, reagents, and associated services to support critical research initiatives in areas like infectious disease, cancer diagnostics, and agricultural genomics. This award appears to be part of Illumina's Indefinite Delivery Contract with the VA, which enables the flexible procurement of its genomic sequencing platforms and support services across multiple VA facilities.

Generated 6/1/25, 2:57 AM